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Abstract
Background: Standardized techniques to detect HIV-neutralizing antibody responses are of great importance in the
search for an HIV vaccine.
Methods: Here, we present a high-throughput, high-content automated plaque reduction (APR) assay based on
automated microscopy and image analysis that allows evaluation of neutralization and inhibition of cell-cell fusion
within the same assay. Neutralization of virus particles is measured as a reduction in the number of fluorescent
plaques, and inhibition of cell-cell fusion as a reduction in plaque area.
Results: We found neutralization strength to be a significant factor in the ability of virus to form syncytia. Further,
we introduce the inhibitory concentration of plaque area reduction (ICpar) as an additional measure of antiviral
activity, i.e. fusion inhibition.
Conclusions: We present an automated image based high-throughput, high-content HIV plaque reduction assay.
This allows, for the first time, simultaneous evaluation of neutralization and inhibition of cell-cell fusion within the
same assay, by quantifying the reduction in number of plaques and mean plaque area, respectively. Inhibition of
cell-to-cell fusion requires higher quantities of inhibitory reagent than inhibition of virus neutralization.
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Background
The assessment of virus specific antibodies plays a central
role in human immunodeficiency virus type 1 (HIV-1)
vaccine development [1]. Thus, evaluation of HIV/AIDS
preventive vaccines requires the development of methods
to assess different properties, including neutralizing cap-
acity, of protective antibody responses. However, no single
assay has so far been reported to detect such protective
antibodies. Instead, a wide range of HIV-1 neutralization
assays and variants thereof have been developed and de-
scribed in the literature [2,3]. These assays are based on
different technologies but they all rely on the principle to
measure reduction of virus infectivity in susceptible cells
in the presence of inhibitory reagents. Likewise, the plaque
reduction assay (PR) is based on virus infectivity and uses
human cell lines (U87.CD4 or GHOST(3)) engineered to
express HIV receptors [4,5].
In parallel, major advances in high-throughput fluores-
cence microscopy and automated, high-content image
analysis tools have paved the way for systematic and quan-
titative study of biological systems [6-10]. Fluorescence-
based imaging assays have been applied to large-scale
analysis to solve biological problems.
Here, we describe an automated PR assay, including
sample preparation, automated image acquisition, and a
computational image analysis pipeline using open-source
software in order to convert the PR assay for HIV
neutralization into a high-throughput, high-content assay.
In addition to quantifying neutralization by reduction of
plaque number, our high-content assay measures plaque
area, permitting studies of cell-cell fusion inhibition. We
compare this assay with manual readout and with other
neutralization assays using a reference panel of inhibitory
reagents, i.e. plasma and monoclonal antibodies. We dem-
onstrate that by the use of image analysis the APR assay is
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converted to a high-throughput and high-content assay,
where plaque area is a measure of cell-cell fusion.
Methods
Plaque Reduction (PR) assay
Infection assays were done by using HIV-1 isolates (of
different subtypes and coreceptor use) and polyclonal
inhibitory reagents (eight HIV-positive and one HIV-
negative plasma), obtained from the Centre for AIDS
Reagents (CFAR) NIBSC, UK, as previously described
[3]. We tested virus neutralization in GHOST(3)-CCR5
and -CXCR4 cell lines stably transfected with CD4, che-
mokine receptors and the Tat-inducible green fluores-
cence protein (GFP) [4,11]. Three days following exposure
of cells to the plasma-virus mixtures, plaque-forming units
(PFU) under the fluorescent microscope are counted to
calculate neutralization as percentage of plaque reduc-
tion (PR) in the sample containing inhibitory reagent:
[1 − (PFU with inhibitory reagent/PFU without inhibi-
tory reagent)] × 100 [5]. For the manual readout the
plaques were counted by eye in separate experiments.
Automated Plaque Reduction assay (APR assay)
To develop the assay in this study, we adapted the prior
protocol for the manual PR assay [4] in 96-well plates
and modified the readout by treating cells with Hoechst
33342 for 20 minutes, washing with PBS, and sealing
plates with aluminum foil prior to automated image ac-
quisition (Supp. Note 1). For the image acquisition, we
used the AxioObserver Z1 with a Zeiss Neofluar Ob-
jective 10X/0.3 with the exposure time 200 ms. The
inner 5 × 3 images of each well (approx. 4.108 mm ×
5.117 mm) were imaged, to be tiled later into a single
mosaic image. Assay quantification was performed by
developing an APR workflow using the freely available
image analysis software CellProfiler (http://www.cell-
profiler.org) [12,13]. The workflow consists of two pipe-
lines comprised of image processing modules optimized
to identify GHOST(3)-CXCR4 and GHOST(3)-CCR5 cells
where HIV infection has activated the GFP marker. The
first pipeline tiles the inner 5 × 3 image sites of each well
into a single mosaic (approx. 4.108 mm × 5.117 mm) so as
not to overestimate by counting plaques that lie on the
image edge twice. A secondary purpose for this pipeline is
to reduce background fluorescence and illumination het-
erogeneities present in the images prior to tiling, plaque
detection and measurement (Figure 1). The second pipe-
line is used for plaque identification and measurement of
parameters such as total cell and plaque count, plaque
area, fluorescence intensity and morphology (Figure 2). In
order to assess cell viability, nuclei are also identified and
counted based on the DAPI stained images. Syncytia are
formed due to merging of multiple cells (Figure 3). Several
parameters in this pipeline can be fine-tuned for plaque
identification; the effect of altering one such parameter is
demonstrated in Figure 4. Detailed instructions on the use
of the PR workflow is described in the Additional file 1
and provided online (http://www.cellprofiler.org/publish-
ed_pipelines.shtml); other optimization considerations are
provided in the module notes that may be viewed when
the pipelines are loaded in CellProfiler.
Details of plaque determination
As is the case for many biological applications, the most
challenging bottleneck in configuring an image analysis
pipeline is the segmentation, defined as the identification
and partitioning of the individual plaques in the image.
The IdentifyPrimaryObjects module in the APR image
analysis pipeline was adjusted to read foreground/back-
ground to match manual reading. The results of the
automatic readout and what would be the corresponding
manual readout within the same experiment are thus
closely similar, if not identical.
Here we describe several key settings contained in the
IdentifyPrimaryObjects module in the plaque identification
Figure 1 The APR assay pipeline tiles the inner 15 images from each well (a) into a mosaic (b). The pipeline includes algorithms for
illumination correction (c) and plaque identification (d). The colors labeling the plaques are used for illustrative purposes and chosen arbitrarily by
the program.
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Figure 2 Mosaic image of a well (a-c-e) is shown along with outlines (b-d-f) as defined by the borders of plaques and nuclei set by the
APR threshold program. All images are taken in the same microscopic field. Plaques (green) and nuclei (blue) are shown as a merged image
(a) or plaques alone (c) or all nuclei (e). The green color labeling of the outlines is used for illustrative purposes only.
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pipeline; these are also described in the module notes
within the CellProfiler user interface:
 Choice of automatic thresholding method: In this
context, thresholding refers to the use of intensity
values to distinguish the image foreground (i.e., the
GFP-expressing plaques) from the background. A
number of automatic thresholding methods are
provided for use in the module; the thresholding
method chosen must not only reliably identify bright
distinct plaques but also the smaller, dim single cells
in order to be sufficiently sensitive. For the PR assay,
the “Robust Background” thresholding method was
used, which assumes a Gaussian intensity distribution
after trimming the brightest and dimmest 5% of pixel
intensities; the threshold is then calculated as the
mean of this distribution plus 2 standard deviations.
 Correction of the threshold value: If the
automatically determined threshold is consistently
too high or too low in all images, it can be further
refined by adjusting a module setting which
multiplies the threshold by a constant value
(“threshold correction factor”). Our automatic
readout was performed after fine-tuning the threshold
correction factor (TCF) on plaque detection in
GHOST(3)- CCR5/CXCR4 cells for HIV-1-infected
and uninfected cases (as explained in the legend for
Figure 4). This selection was made manually by
careful review of many plates and pictures. and
verified through comparison of uninfected and
Figure 3 A magnified picture of syncytia (green) and nuclei (blue) is shown as a merged image (a) along with the outlines (b). Image of
syncytia (c) along with the outlines (d) as well as nuclei inside the syncytia (e) with the outlines (f) clearly show how nuclei cluster inside
syncytia. The green color labeling the outlines is used for illustrative purposes only.
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HIV-1 infected GHOST(3) cultures. Care is required
in correction factor selection since an excessively high
value will identify only the brightest plaques (i.e., yield
false negatives) and underestimate the plaque area in
GFP-positive images, whereas a value that is too low
will detect false positives in GFP-negative images
(Figure 4). A threshold correction factor of 1.6 was
found to be optimal for this assay.
 Selection of the lower threshold limit: In instances
where the image is GFP-negative (i.e., no plaques),
the automatic threshold value may be too low and
therefore detects false positives. A lower threshold
bound can be set as a precautionary measure by
empirically estimating the GFP-negative signal
across several images. For the PR assay, the lower
threshold bound was set to 0.013.
 Object exclusion based on plaque size: The upper
and lower bounds for the typical diameter of a
GFP-identified plaque can be adjusted to exclude
spurious foreground regions, thereby precluding
false positives. This size range was set to 4–150 pixels
after calculating the mean diameter of a number of
individual GHOST(3) cells in brightfield mode
(data not shown).
PBMC- and pseudovirus- based neutralization assays
The detailed methodologies of the peripheral blood
mononuclear cell (PBMC)- and Env (gp160) pseudotyped
virus (PSV)-based neutralization assays are available on
the EUROPRISE website (http://www.europrise.org/neut-
net_sops.html). In brief, seven laboratories performed the
PBMC-based assay, where virus isolates were used with
PBMC (isolated from buffy coats of HIV-negative blood
donors) as target cells. The PSV-based assay was per-
formed by six different laboratories as a single cycle assay
and by one laboratory as a multiple cycle infection assay
with engineered cell lines as target cells.
Statistics
The non-parametric Spearman rank statistical analysis
was used to calculate correlations between findings of
the automated and manual plaque reduction assays and
neutralization to change in plaque area. For comparison
of the three different neutralization assays in relation to
virus neutralization sensitivity and plasma neutralization
capacity, as well as the mean plaque area of different un-
inhibited HIV-1 isolates the non-parametric Kruskal
Wallis test, with Dunn’s post test, was used. Normalized
mean plaque area for virus-plasma combinations, at IC50,
IC75 and IC90, was evaluated according to Friedman’s test
and Dunn’s Post Test.
Results
Comparison of manual and APR readout
We compared the manual and automated readouts
using 72 virus-plasma combinations, including eight
combinations with HIV-negative plasma (Figure 5). In
46 cases (64%), the manual and automatic readouts of
Figure 4 Effect of the threshold correction factor (TCF) on plaque detection in GHOST(3)- CCR5/CXCR4 cells for (a) HIV-1-infected and
(b) uninfected cases. The TCF is located in the IdentifyPrimaryObjects module in the APR image analysis pipeline and affects the stringency or
leniency of foreground/background thresholding. Column 1: Fluorescence microscopy images with HIV-1-infected cells expressing GFP (green)
and nuclei stained with DAPI (blue). Columns 2 – 4: GFP-expressing syncytia detected for various values of the TCF, as noted in the column title.
The colors labeling the syncytia are used for illustrative purposes and chosen arbitrarily.
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50% inhibitory concentration (IC50) were within two-
fold of each other and in 12 cases (17%) the difference
was within a 2- to 3-fold range. This is an insignificant
degree of variation in accordance with the accepted
convention used in clinical virology (e.g., if serial 2-fold
dilutions of antibodies are used). In the remaining 14
virus-plasma combinations (19%), variation of IC50 was
more than 3-fold between manual and automatic read-
outs. Further examination of this latter group revealed
that in 11 out of 14 combinations, the automatic readout
was more sensitive than the manual readout in detecting
neutralization (denoted as triangles above the diagonal
line in Figure 5). These 14 points were not the result of an
image analysis artifact, since no false positive background
was detected with the negative plasma and the manual
and automatic readout of other inhibitory reagent-virus
combinations run on the same plate and day were in close
agreement. Taken together, the APR assay detected
neutralization similarly, but with generally increased sensi-
tivity, as compared to the manual PR readout.
Comparison of APR assay with other HIV-1 neutralization
assays
The APR assay has been developed within the frame-
work of an international network for comparison of HIV
neutralization assays [3]. Comparisons on the IC50 level
with other virus infection assays, including the PBMC and
pseudovirus (PSV) assays using plasma and monoclonal
antibodies, showed that sensitivities were dependent on
both virus and plasma (Figure 6a and b). No statistical dif-
ferences were found when comparing results of the APR
and the PBMC-based assays when considering either virus
neutralization sensitivity or plasma neutralization capacity.
When comparing the APR and the PSV assays, virus
neutralization sensitivity was statistically similar for seven
out of eight viruses (Figure 6a); neutralization of 92UG024
was detected with higher sensitivity with the PSV assay as
compared to both the APR assay (p < 0.05) and the PBMC
assay (p < 0.001) (Figure 6a). For the neutralization cap-
acity of plasma, results generated from the APR and the
PSV assay were not significantly different with six out of
eight plasma tested (Figure 6b). The exceptions were
plasma ARP521 and ARP522, which displayed higher
neutralization titers in the PSV assay compared with the
APR assay (p < 0.01). We noted that it was particularly the
use of ARP521 and ARP522 in combination with the
92UG024 and SF162 viruses that influenced the results.
Overall, the sensitivity of the automatic PR assay was in
the range of the other assays.
High-content readout by the APR assay allows analysis of
cell-cell fusion inhibition
We next evaluated the capacity of the APR assay to
quantify the size of the plaque area, as a measure of cell-
cell fusion. Changes in mean plaque area were evaluated
in single virus-inhibitory reagent combinations. Results
showed that quantification of plaque area was possible.
Analysis of the relationship between neutralization level
and plaque area across virus-inhibitory reagent combina-
tions where IC50, IC75 and IC90 was achieved, revealed
that the mean plaque area was significantly reduced at
90% inhibitory concentration (IC90) but not at IC50
(Figure 7), indicating that the level of neutralization seems
to be important for inhibition of virus-mediated cell-cell
fusion. Furthermore, the decrease in plaque area was
statistically significant only when neutralization reached
IC90 with plasma dilution exceeding 1:50 or an antibody
concentration above 6 μg/mL (for TriMab). This was
the case for four inhibitory reagent-virus combinations
(Figure 8a, c, e and Additional file 1: Table S1).
Fourteen combinations that reached IC90 with a plasma
dilution lower than 1:50 and 11 combinations that reached
IC50 showed a trend towards decreased plaque area
but could not be statistically confirmed (exemplified in
Figure 8b). Apparently, the steep fall in neutralizing ac-
tivity upon dilution provided too few points for curve
fitting. Twelve other inhibitory reagent-virus combina-
tions that showed neutralization did not display reduc-
tion in mean plaque area (exemplified in Figure 8d). As
Figure 5 Comparison of neutralization sensitivity (IC50) of
manual and automated readout in 72 virus-plasma combinations,
including eight with HIV-negative plasma (denoted with a big X
and arrow). The manual and automated readouts were from separate
experiments. Readouts that do not vary more than 2-fold are denoted
with x. Differences within a 2-3-fold range are depicted with a ring, and
remaining virus-plasma combinations where the variation was >3-fold
between manual and automatic readouts is depicted with a triangle.
Triangle points are generally above the diagonal line indicating higher
sensitivity of the automated readout. Statistically significant correlation
between automated and manual readout according to Spearman rank
(p < 0.0001, r = 0.8104).
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expected, those inhibitory reagents lacking neutralizing
activity against a particular virus did not affect the plaque
area (e.g., Figure 8f). We did not identify a particular re-
agent capable of reducing plaque area of all viruses.
For quantitative analysis of plaque reduction we intro-
duced a new nomenclature, ICpar (inhibitory concentration
for plaque area reduction). ICpar indicates the concen-
tration at which the antibody causes a decrease in
plaque area, e.g., ICpar50 is a 50% reduction in plaque
area. IC90 and ICpar50 values were similar for most
virus-antibody combinations (Figure 8 and Additional
file 1: Table S1) indicating that inhibition of cell-to-cell
Figure 6 Comparisons of neutralization results generated by the automated plaque reduction (APR) assay with that of pseudovirus
(PSV) based and peripheral blood mononuclear cell (PBMC) based assays. Circular “radar” plots of 50% inhibitory concentration-(IC50) values
across (a) viruses and (b) plasma for the PSV assay (blue lines), the PBMC assay (red lines) and the APR assay (green lines). The radial axes extending
from the plot center represent a particular (a) plasma and (b) virus for each axis. The radial scale is normalized, with the center representing no
neutralization, the concentric grid lines representing 2-fold dilution steps and outermost lines representing the highest neutralization (IC50 > 1280). For
each virus-plasma combination, the geometric mean IC value is calculated and plotted for each assay, with the points connected within a given assay.
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fusion requires higher quantities of inhibitory reagent
than inhibition of virus cell entry and replication.
Virus-induced cell-cell fusion characteristics based on
plaque area readout
We next analysed the size of the plaque area in rela-
tion to the different virus isolates. The mean plaque
area of each virus yielded a characteristic size distribu-
tion (Figure 9), regardless of virus titration (data not
shown). However, neither coreceptor use nor subtype
of HIV-1 correlated to plaque area, as both X4 and R5
viruses and subtype B and C viruses were found across
the size distribution. It is interesting to note that the
92UG024 virus, yielding relatively small plaques, was
used in five of the 11 cases where automatic readout
was more sensitive, suggesting that the small plaques
may be more difficult to score by eye.
Discussion
Here we describe a novel image-based methodology for
assaying HIV neutralization in an automated high-content
manner. Our high-content assay allows, for the first time,
evaluation of both HIV neutralization and inhibition of
cell-cell fusion within the same assay. This is achieved by
quantifying the reduction in number of plaques and mean
plaque area, respectively. The image analysis pipeline for
the APR assay in GHOST(3) cells is based on the freely
available CellProfiler software [12] and has now been
optimized and adapted for automated reading. Automa-
tion offers many advantages: it is higher throughput, stan-
dardized, and inexpensive compared both to the manual
PR assay and the classic virus infection assay performed in
peripheral blood mononuclear cells (PBMC). Automated
image analysis increases the objectivity of the plaque
counting demonstrated by the very low intra-well vari-
ation among triplicate wells (data not shown) as well as
low background in the negative controls.
A striking feature of the image-based approach is that
it allows extraction of additional phenotypic features of
viruses, including cell-cell fusion capacity. We observed
differences between the eight HIV-1 isolates used in the
present study. In fact, based on statistically significant
differences in mean plaque area, viruses could be divided
into two groups yielding large or small plaques. Large
plaques may result from fusion of a higher number of
cells than small plaques. It has been suggested that virus
ability to mediate cell-cell fusion, i.e. syncytia, depends
on the strength of the interaction of viral envelope pro-
tein with CD4 and coreceptors [14,15]. In addition, Env
clustering and mobility in the cell membrane may influ-
ence the outcome of syncytia formation [16].
Our results show that a higher concentration of inhibi-
tory reagent was needed to get a reduction in plaque
area than that needed for neutralization. This was previ-
ously proposed by Yee et al. [17] and given the explan-
ation that the interaction of the envelope glycoproteins
gp120/gp41 (Env) with cell membrane CD4 may be dif-
ferent during cell-cell fusion than during virus-cell
membrane fusion [18]. It is plausible that the molecular
organization and surface density of gp120/gp41 may be
different in Env-expressing cells and HIV-1 virions. In-
deed, Purtscher et al. [19] proposed, similarly to what we
show, that elevated concentrations of antibody are ne-
cessary to inhibit fusion between infected and target
cells, and suggested this to be due to higher levels of
gp120/gp41 expressed on the surface of infected cells as
compared to the viral envelope. Interestingly, it was re-
cently shown, in an HIV-1-infected humanized mouse
model, that infected T cells form contacts with unin-
fected cells, and when the frequency of these contacts
was reduced, plasma viremia was significantly decreased,
strongly suggesting a role for cell-cell contacts in sys-
temic viral spread [20]. Thus, it is conceivable that cell-
cell fusion inhibition capacity of an antibody has a role
in mitigating pathogenesis and may also be required for
an effective HIV vaccine.
Antibody assessment plays a central role in HIV-1
vaccine development where, analogous to other virus
infections, virus neutralization is considered particu-
larly important. Accordingly, international comparisons
of a wide range of HIV-1 neutralization assays have
been performed and showed that no assay alone detects
Figure 7 Plaque area for different virus-plasma combinations
and inhibitory reagent concentrations that reached IC90. Percent
plaque area relative to uninhibited virus (100) is shown for virus-plasma
combinations where 50, 75 and 90% inhibitory concentrations (IC50,
IC75 and IC90) could be determined. The plaque size of the same
virus-plasma combinations at different IC values are connected.
Statistically significant differences are indicated according to
Friedman’s test and Dunn’s Post Test, **p < 0.01; ***p < 0.001.
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neutralization over the entire spectrum of virus-reagent
combinations [2,21]. The APR assay has also been stan-
dardized and compared with other HIV neutralization
assays within the framework of an international collab-
oration, Neutnet [2,3]. As with the other assays, the
sensitivity of our assay was dependent on both the neu-
tralizing reagent and the virus. Thus the APR assay can
be considered an information-rich alternative to the
PBMC and PSV assays.
Conclusions
Here we report on a novel image-based automated
plaque-reduction assay where both HIV neutralization
and inhibition of cell-cell fusion can be analyzed, for the
first time within the boundaries of the same assay for-
mat. This high-content assay may be used as a tool for
evaluation of multiple antibody effector functions, by
ways of quantifying the reduction in number of plaques
and mean plaque area, respectively. The image analysis
Figure 8 Relationship between neutralization and plaque area. _______, mean plaque area (μm, y axis on the right) indicated with a solid line;
−————, neutralization (NAc%, y axis on the left) indicated with a broken line in each panel and ICpar50 values are indicated with vertical
dotted lines in panel a, b and c. The plaque area without addition of inhibitory reagent (virus only) is indicated by a horizontal line on the y axis on
the right. Virus-plasma combinations: (a) ARP516-SF162; (b) ARP517-QH0692; (c) TriMab-SF162; (d) TriMab-QH0692; (e) ARP517-MN(P); (f) ARP516-MN
(P). R and p values are given for the correlation of neutralization and plaque area according to Spearman rank.
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platform described herein can be further developed with
the potential to study additional features of antibody-
virus-cell interactions, which may prove important in
antibody-based HIV vaccine design.
Additional file
Additional file 1: Table S1. High-throughput, automated, image-based
assay for HIV neutralization by plaque reduction.
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